ORIGINAL ARTICLE
dilemma than when such granuloma is extracranial. In such situations, delaying immunomodulators may result in the progression of a non-infectious etiology and irreversible neurological impairment. There is scarce data on the treatment outcome of this rare condition. Hence, the optimal management of ICGNs remains unclear. We reviewed the clinicopathological characteristics and treatment outcomes of ICGNs at our institution. Our observations provided further insight into the management strategy for ICGNs.
METHODS
We searched the pathology database of St. Michael's Hospital, Toronto for "granuloma" and "brain". We retrieved 42 intracranial granulomas between 2000 and 2008. We reviewed and selected intracranial granulomas with caseating necrosis seen on hematoxylin-phloxine-saffron staining (17 patients). We next excluded eight caseating granulomas in which an infectious agent was identified using rRNA Amplified Mycobacterium tuberculosis Direct Test (AMTD), Ziehl-Neelsen, Auramine Rhodamine, Fite, Silver Methenamine, Periodic Acid-Schiff, Steiner and Gram stains and mycobacterial and routine cultures (seven Mycobacterial and one fungal infections). We excluded one patient for whom tissue AMTD and mycobacterial culture were not available. The remaining eight patients, in whom all the above examinations were negative, are reported here as ICGNs.
The research ethics board of St. Michael's Hospital approved the study.
RESULTS
We identified eight patients with ICGN (four females and four males). Table 1 summarizes the demographic data and clinical presentation of patients with ICGN. The average age on presentation was 46 years (range 21-69 years; SEM = 5.8 years).
The most common presentation was seizures in four patients, followed by confusion in two patients. Somatosensory symptoms were found in one patient (left-sided arm and leg tingling). Other presenting symptoms were bilateral visual loss, double vision and ataxia. While one patient reported malaise and weight loss, none had fever, chills, headache or neck-stiffness. None of the patients reported tuberculosis exposure, although two patients had previously lived in tuberculosis endemic areas. Other tuberculosis risk factors (age, HIV infection, malnutrition, recent measles, alcoholism, underlying malignancy and immunosuppression) were absent in all patients.
Selected laboratory data of patients in our series are summarized in Table 2 . None of the patients tested were found to have an elevated angiotensin converting enzyme (ACE) level.
All patients had normal corrected calcium levels (average = 2.3 mmol/L; SEM = 0.3 mmol/L). Erythrocyte sedimentation rate (ESR) was measured in only four patients (range 2-88 mm/hr), and was elevated in three. Antinuclear antibody (ANA) was negative in all six patients in whom it was measured. In addition to the laboratory data summarized in table 2, there were negative  Treponema pallidum IgG and IgM, VDRL, toxoplasma IgG,  Lyme, cytomegalovirus serology, extractable nuclear antigens, anti-neutrophil cytoplasmic antibodies, rheumatoid factor and complements in four tested patients.
Cerebrospinal fluid (CSF) analysis was available in four patients ( Table 2 ). One patient had three lumbar punctures and two other patients had two lumbar punctures. While three patients had elevated CSF leukocytes ranging from 23 to 322 white blood cells (WBC)/mm 3 , one patient had three WBC/mm 3 . In all cases, there was lymphocytic predominance. All CSF samples had elevated protein levels ranging from 0.75 to 2.94 g/L. Cerebrospinal fluid glucose was decreased in all but one sample (range 1-3.7 mmol/L). All CSF samples were negative for Ziehl-Neelsen stain, AMTD, mycobacterial fluorescent smear and myco-bacterial culture. Additionally, all CSF samples had negative Polymerase chain reaction (PCR) for herpes simplex virus group and West-Nile virus, gram stain, bacterial and fungal cultures, cryptococcal antigen, cytology and VDRL.
Neuroimaging findings are summarized in Table 3 . Contrast enhanced magnetic resonance imaging (MRI) of brain was available in five patients. In four patients, MRI of brain showed multiple supra-tentorial intraparenchymaal T2/FLAIR hyperintense lesions. These lesions showed homogeneous gadolinium enhancement. Meningeal gadolinium enhancement was observed in all of these patients ( Figure 1 ). In three of these patients, similar lesions were also found in the infra-tentorial areas of the brain. One patient had a single supratentorial T2/FLAIR hyper-intense lesion with homogenous gadolinium enhancement. This patient did not have meningeal enhancement. Contrast enhanced computed tomogram (CT) of brain was available in three patients, who didn't have an MRI of brain. Two of these patients had single ring-enhancing supra-tentorial intraparenchymal lesions and the other had a single irregularlyenhancing supra-tentorial intraparenchymal lesion. Hydrocephalus was seen in two patients, one of whom had a ringenhancing lesion. Calcification of the lesion was seen in two out of the three CT scans of brain. Magnetic resonance imaging of Chest X-ray and CT scan was available in all patients. Hilar lymph nodes were only detected on two chest CT scans, one of which was biopsied. Whole body gallium scans, performed in five patients, were negative.
Tissues examined included brain parenchyma (five patients), meninges (two patients) or both (one patient). One patient had hilar lymph node biopsy in addition to brain and meninges. Focal areas of granulomatous inflammation containing aggregations of histiocytes with caseating necrosis were seen on all biopsies ( Figure 2 ), including one hilar lymph node biopsy. Immunocytochemical analysis of the cellular infiltrate revealed predominately CD68 positive macrophages and scattered CD3 positive T-lymphocytes and CD20 positive B-lymphocytes. No microorganism was identified in extensive tissue examination, as described in methods.
Clinical and radiological responses to treatment are detailed in therapy prior to biopsy. The attending physicians initiated immunomodulation therapy without a trial of anti-mycobacterial therapy in Patients 1, 6 and 7 because of their low clinical suspicion for tuberculosis and high clinical suspicion for sarcoidosis. In Patients 2 and 3, immunomodulation therapy was started one to two months after an initial anti-mycobacterial therapy because of clinical and/or radiological worsening. Both of these patients developed bilateral leg weakness during this initial anti-mycobacterial therapy necessitating wheelchair for ambulation. Patients 5 and 8 showed neither improvement nor worsening on anti-mycobacterial therapy over 26 and 48 months of follow-up. Given no clinical progression, immunomodulation therapy was not tried in these patients. Overall, five out of seven treated patients clearly responded to immunomodulators (Patients 1, 2, 3, 6 and 7). This included two patients with a delay of one to two months in initiation of immunomodulation therapy due to an unsuccessful trial of antimycobacterial therapy (Patients 2 and 3), as well as three patients with early treatment with immunomodulation therapy in the other three patients (Patients 1, 6 and 7). Prednisone alone was used in two patients and a combination of prednisone and azathioprine in three patients. Prednisone was started at 1 mg/kg with slow taper over six months. One patient relapsed while prednisone was tapered. Prednisone had to be restarted. Azothioprine was started at 50 mg per day and titrated up with final dose of 100 to 150 mg per day. Radiologically, immunomodulation therapy resulted in complete resolution of the lesions in three (Patients 2, 6 and 7) and decrease in lesion size in another (Patient 1). Clinically, three patients had improved ambulation and went from using a wheelchair to ambulating independently (Patient 1, improved ataxia) and to ambulating with a walker (Patients 2 and 3, improved leg weakness). One patient, who also had complete radiological resolution, remained seizure free 32 months after presentation (Patient 6). One patient was seizure-free and had improvement in her cognitive impairment to the extent that she became employed (Patient 7). Recurrence was noted after the tapering of immunomodulation therapy in three of the five patients (Patients 2, 3 and 7) and necessitated reinstating immunomodulation therapy. In two patients who did not receive immunomodulators, there was no clear response to anti-mycobacterial therapy. Figure 1 shows complete radiological resolution on immunomodulators, after an initial worsening on anti-mycobacterial therapy (Patient 2).
DISCUSSION
This series describes an uncommon clinical occurrence, designated as ICGN, defined by negative infectious investigations in the presence of intracranial caseating granulomas. The neurological manifestations were as expected, but the absence of constitutional symptoms was noteworthy, especially in view of the elevated cells and protein and decreased glucose in CSF. The enhancing intrapenchymal lesions were often, but not always, accompanied by meningeal enhancement. Most remarkably, immunomodulation therapy was required in the majority of the patients. In contrast, there was no clear benefit of anti-mycobacterial therapy. These observations suggest an earlier trial of immunomodulation therapy may be beneficial in the management of ICGNs.
Central nervous system (CNS) involvement occurs in a small fraction of tuberculosis patients 6 . This condition carries a high mortality necessitating prompt treatment 6 . Detection of mycobacteria in CSF by Ziehl-Neelsen staining or mycobacterial culture confers a variable sensitivity of 20% to 90% (reviewed in Rock et al 6 . The sensitivity of staining or culture for detection of mycobacteria has not been studied separately in CNS tissue. In a study that included CNS tissue amongst other tissues, staining and culture detected mycobacteria with 42% and 55% sensitivities, respectively 7 . Polymerase chain reaction-based CSF assays such as AMTD have higher sensitivities 6 . In tissue, PCR-based assays confer a sensitivity of 70-80% with negative predictive value of 88-97% 7, 8 . The data on the negative predictive value of a combination of the above tests is scarce. In one study comparing these tests among 20 patients with clinically confirmed tuberculous pericarditis, all tissues were positive for at least one of Ziehl-Neelsen examination, mycobacterial culture or PCR 9 . In another study examining 115 tissue samples from various organs showing granuloma and negative Ziehl-Neelsen examination, 13 samples were found to be also negative for mycobacterial culture and PCR 10 . However, unlike the former study, the clinical diagnosis of tuberculosis in these patients did not include response to treatment on followup. While false negative Ziehl Neelsen, mycobacterial culture and PCR examinations is a possibility, response to treatment in our patients was not compatible with a diagnosis of mycobacterial infection. Hence, the combination of the above tests was clinically more meaningful than the observation of caseating granulomas in histopathologic examinations. The nature of the caseating granulomas in our patients remains unclear. An atypical presentation of sarcoidosis is the main diagnostic consideration. Granulomata of sarcoidosis are classically non-caseating. Any presence of caseation within sarcoid granulomas necessitates a re-examination of the tissue to ensure an infectious etiology has not been overlooked 11 . Two of our patients had hilar lymphadenopathy, which supported a diagnosis of sarcoidosis. All our tested patients including those with hilar lymphadenopathy had normal ACE levels. However, the sensitivity of serum ACE in sarcoidosis is only 50-60% 12 . ANCA-associated vasculitides, i.e. Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome, are another diagnostic consideration. Among these, Wegener's granulomatosis can show both granulomas and necrosis, although necrosis is limited to the vessel walls and does not produce a picture of caseating granulomas 13 . ANCA was negative in all our tested patients. Granulomas can be seen in other vasculitides such as giant cell arteritis and Takayasu disease, but are typically non-necrotizing 13 . Given the uncertainty regarding the etiology underlying the observed caseating granulomas, we grouped all the patients under ICGN.
We find the designation of ICGN clinically useful, despite lacking etiological significance. The majority of our patients (five out of seven) required immunomodulation therapy. Three patients had complete radiological resolution of their lesions on prednisone and azathioprine. This suggests that the clinical improvement observed in these patients resulted from a response of the disease process to the treatment rather than mere reduction in edema. Two of these patients had worsening on antimycobacterial treatment. Hence, when a rigorous investigation that includes tissue examination fails to identify an infectious cause in patients with intracranial caseating granulomas, a designation of ICGN and an early trial of immunomodulation therapy may be beneficial.
CONCLUSIONS
Our study was limited by the retrospective quality of data. Ideally, a double-blind randomized clinical trial is needed to establish the optimal management of ICGNs. However, given the scarcity of ICGNs, a retrospective case series is the only feasible design to answer the questions approached hereby.
